Back to Search
Start Over
Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
- Source :
-
Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 May; Vol. 19 (5), pp. 1913-1924. Date of Electronic Publication: 2022 Nov 12. - Publication Year :
- 2023
-
Abstract
- Introduction: Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences.<br />Methods: In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aβ42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aβ42/p-tau ratio.<br />Results: All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aβ42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94).<br />Discussion: Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD.<br />Highlights: Patients with an Alzheimer's disease cerebrospinal fluid (AD CSF) profile have higher plasma phosphorylated tau (p-tau) levels than the non-AD CSF profile group. All plasma p-tau biomarkers significantly discriminate patients with an AD CSF profile from the non-AD CSF profile group. Janssen p-tau217, ADx p-tau181, and Lilly p-tau217 in plasma show the highest accuracy to detect biologically defined AD. Janssen p-tau217, ADx p-tau181, Lilly p-tau217, Lilly p-tau181, and UGot p-tau231 in plasma show performances that are comparable to their CSF counterparts.<br /> (© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
- Subjects :
- Humans
Amyloid beta-Peptides cerebrospinal fluid
Biomarkers blood
Biomarkers cerebrospinal fluid
Enzyme-Linked Immunosorbent Assay
Alzheimer Disease cerebrospinal fluid
Cognitive Dysfunction blood
Cognitive Dysfunction cerebrospinal fluid
Immunoassay
tau Proteins blood
tau Proteins cerebrospinal fluid
tau Proteins metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1552-5279
- Volume :
- 19
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Alzheimer's & dementia : the journal of the Alzheimer's Association
- Publication Type :
- Academic Journal
- Accession number :
- 36370462
- Full Text :
- https://doi.org/10.1002/alz.12841